Menten AI vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 AI cyclic peptide drug discovery with Bristol Myers Squibb collaboration May 2024; $4.15M Khosla/Uncork/Feld-backed using ML+quantum computing for peptide optimization competing with Relay Therapeutics for pharma licensing.
About
Menten AI is a San Francisco-based AI drug discovery company — backed by Y Combinator (W20) with $4.15 million in total funding from Y Combinator, Khosla Ventures, Uncork Capital, Feld Ventures, Mana Ventures, Quain Investments, Society Health, and Volpini Ventures — developing peptide and protein therapeutics using machine learning and quantum computing to design novel cyclic peptide drug candidates for pharmaceutical licensing partnerships, completing a research collaboration with Bristol Myers Squibb in May 2024. Founded in 2018, Menten AI applies advanced AI algorithms for cyclic peptide optimization and protein structure design with a business model centered on licensing proprietary algorithms and drug candidates to pharma partners rather than developing therapeutics through full clinical development.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.